See more : Newcrest Mining Limited (NCMGY) Income Statement Analysis – Financial Results
Complete financial analysis of BeiGene, Ltd. (BGNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BeiGene, Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Veren Inc. (VRN.TO) Income Statement Analysis – Financial Results
- Cullman Bancorp, Inc. (CULL) Income Statement Analysis – Financial Results
- Pacton Gold Inc. (PACXF) Income Statement Analysis – Financial Results
- SHANGHAI JINJIANG SHIPPING (GP) CO (601083.SS) Income Statement Analysis – Financial Results
- Namsun Aluminum Co., Ltd. (008355.KS) Income Statement Analysis – Financial Results
BeiGene, Ltd. (BGNE)
About BeiGene, Ltd.
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.46B | 1.42B | 1.18B | 308.87M | 428.21M | 198.22M | 238.39M | 1.07M | 8.82M | 13.04M | 11.15M |
| Cost of Revenue | 379.92M | 1.93B | 1.62B | 1.37B | 998.53M | 707.71M | 273.99M | 98.03M | 58.25M | 21.86M | 13.46M |
| Gross Profit | 2.08B | -511.06M | -447.86M | -1.06B | -570.32M | -509.49M | -35.61M | -96.96M | -49.43M | -8.83M | -2.32M |
| Gross Profit Ratio | 84.55% | -36.09% | -38.07% | -342.10% | -133.19% | -257.03% | -14.94% | -9,061.96% | -560.73% | -67.72% | -20.77% |
| Research & Development | 1.78B | 1.64B | 1.46B | 1.29B | 927.34M | 679.01M | 269.02M | 98.03M | 58.25B | 21.86M | 13.46M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 195.39M | 62.60M | 20.10M | 7.31M | 6.93M | 3.14M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.50B | 1.28B | 990.12M | 600.18M | 388.25M | 195.39M | 62.60M | 20.10M | 7.31M | 6.93M | 3.14M |
| Other Expenses | 3.50M | -1.64B | 750.00K | 846.00K | 1.33M | 894.00K | 250.00K | -2.49M | -916.00K | 600.00K | 584.00K |
| Operating Expenses | 3.29B | 1.28B | 990.87M | 601.02M | 389.58M | 196.28M | 62.85M | 20.10M | 7.31M | 6.93M | 3.14M |
| Cost & Expenses | 3.67B | 3.21B | 2.62B | 1.97B | 1.39B | 903.99M | 336.84M | 118.13M | 65.56M | 28.79M | 16.61M |
| Interest Income | 0.00 | 74.18M | 13.51M | 2.00M | 9.13M | 0.00 | 0.00 | 0.00 | 1.79M | 40.00K | 2.00K |
| Interest Expense | 0.00 | 52.48M | 0.00 | 338.00K | 9.13M | 13.95M | 0.00 | 383.00K | 1.23M | 3.55M | 3.16M |
| Depreciation & Amortization | 87.68M | 66.28M | 46.46M | 31.79M | 18.62M | 9.89M | 4.59M | 1.91M | 1.55M | 1.56M | 1.59M |
| EBITDA | -1.12B | -1.73B | -1.39B | -1.63B | -941.27M | -695.38M | -93.70M | -115.15M | -55.20M | -14.20M | -3.15M |
| EBITDA Ratio | -45.74% | -126.34% | -122.25% | -536.41% | -223.85% | -342.64% | -36.12% | -10,958.32% | -616.24% | -101.03% | -24.64% |
| Operating Income | -1.21B | -1.79B | -1.44B | -1.66B | -959.89M | -705.77M | -98.46M | -117.06M | -56.75M | -15.76M | -5.46M |
| Operating Income Ratio | -49.12% | -126.40% | -122.31% | -536.69% | -224.16% | -356.05% | -41.30% | -10,940.19% | -643.66% | -120.88% | -48.96% |
| Total Other Income/Expenses | 381.90M | -171.37M | 147.00K | 39.49M | 16.31M | 15.94M | 7.39M | -2.10M | -357.00K | -2.79M | -2.44M |
| Income Before Tax | -825.84M | -1.96B | -1.44B | -1.62B | -943.59M | -689.83M | -91.06M | -119.16M | -57.10M | -18.55M | -7.89M |
| Income Before Tax Ratio | -33.59% | -138.50% | -122.30% | -523.90% | -220.35% | -348.01% | -38.20% | -11,136.73% | -647.71% | -142.28% | -70.81% |
| Income Tax Expense | 55.87M | 42.78M | -25.23M | -17.67M | 6.99M | -15.80M | 2.24M | 54.00K | 872.00K | 763.00K | 719.00K |
| Net Income | -881.71M | -2.00B | -1.41B | -1.60B | -950.58M | -673.77M | -93.11M | -119.22M | -57.10M | -18.28M | -7.49M |
| Net Income Ratio | -35.86% | -141.52% | -120.15% | -518.18% | -221.99% | -339.91% | -39.06% | -11,141.78% | -647.71% | -140.22% | -67.22% |
| EPS | -8.45 | -19.43 | -15.23 | -19.17 | -15.83 | -12.15 | -2.04 | -3.00 | -1.81 | -0.35 | -0.14 |
| EPS Diluted | -8.45 | -19.43 | -15.23 | -19.17 | -15.83 | -12.15 | -2.04 | -3.00 | -1.81 | -0.35 | -0.14 |
| Weighted Avg Shares Out | 104.39M | 103.13M | 92.79M | 83.47M | 60.05M | 55.44M | 45.54M | 39.68M | 31.52M | 52.66M | 52.66M |
| Weighted Avg Shares Out (Dil) | 104.39M | 103.13M | 92.79M | 83.47M | 60.05M | 55.44M | 45.54M | 39.68M | 31.52M | 52.66M | 52.66M |
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
BeiGene regains rights for cancer drug after Novartis deal termination
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
7 Best Cancer Stocks to Invest in Now
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
Source: https://incomestatements.info
Category: Stock Reports